Cargando…
Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
Autores principales: | Moliner, L., Spurgeon, L., Califano, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958277/ https://www.ncbi.nlm.nih.gov/pubmed/36791668 http://dx.doi.org/10.1016/j.esmoop.2023.100879 |
Ejemplares similares
-
Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017) -
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022) -
Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020) -
Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023) -
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
por: Morabito, Alessandro
Publicado: (2018)